Beta Innov

Beta-Innov is a French biotechnology company dedicated to identifying and validating new therapeutic targets for the treatment of diabetes. Located in the Genopole biocluster in Évry, the company leverages its proprietary Beta-Screen platform, which utilizes human pancreatic islets for high-throughput phenotypic screening. This technology allows for the identification of compounds and biological pathways that promote the survival, function, and regeneration of insulin-producing beta cells. By focusing on human-centric models early in the discovery process, Beta-Innov aims to improve the translatability of its findings into effective therapies for Type 1 and Type 2 diabetes. The company's approach addresses the underlying cause of diabetes—the loss of functional beta cell mass—rather than just managing symptoms.